Category: Miscellaneous

A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer

January 22, 2026
| No Comments
| Cancer - Colon, Miscellaneous

Comment: A central issue in palliative oncology is the historical focus on aggressive salvage therapies that frequently lead to negative impacts on QOL rather than measurable survival gains. Metronomic capecitabine reverses this risk-benefit calculation, delivering a median overall survival of 18 months in responders while reporting no treatment-related deaths or severe toxicities. In a population […]

Read More »

The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug

December 13, 2025
| No Comments
| Cancers, Miscellaneous, Repurposed Drugs - Anti-parasitics, Metformin

Comment: While the mechanism of repurposing ivermectin is mechanistically sound, we must be careful not to conflate “safe for occasional parasitic use” with “safe for chronic oncologic use.” The authors rely on a safety profile established at low, intermittent doses (150–200 mcg/kg). However, achieving the antitumor concentrations cited here likely requires sustained dosing up to […]

Read More »

Real-world impact of postmastectomy radiotherapy in T1–2 breast cancer with one to three positive lymph nodes

November 16, 2025
| No Comments
| Cancer - Breast, Mastectomy-Lumpectomy, Miscellaneous, Radiation Therapy

Comment: This SEER data review of T1-2N1 breast cancer patients continues the trend we’ve been observing: Postmastectomy Radiotherapy (PMRT) rarely translates into a statistically significant survival advantage in the modern setting. After adjusting for selection bias using Propensity Score Matching (PSM), the 5-year Breast Cancer-Specific Survival (BCSS) was comparable between the PMRT and non-PMRT groups. […]

Read More »

Associations of Commonly Used Concomitant Medications With Survival and Adverse Event Outcomes in Breast Cancer

November 11, 2025
| No Comments
| Cancer - Breast, Cancers, Miscellaneous

Comment: This large pooled analysis gives us several interesting and important pieces of information. Although this study was with breast cancer patients, there is no reason to believe it doesn’t apply to every cancer. The magnitude of risk associated with common, non-oncology drugs is genuinely alarming. PPI use, a near-universal practice for GI prophylaxis and […]

Read More »

Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?

November 2, 2025
| No Comments
| Miscellaneous

Comment: This 2017 article’s real contribution here isn’t the narrative review—which, as is too selective to be high-quality—but the new VICTOR-2 subgroup data. While a 35.7% Clinical Benefit Rate in an elderly (median age 69) metastatic TNBC population is certainly interesting, it’s from a tiny, single-arm cohort of 28 patients. This paper highlights metronomic chemotherapy […]

Read More »

Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key

November 2, 2025
| No Comments
| Miscellaneous

Comment: This paper tries to identify the true clinical niche for Metronomic Chemotherapy: adjuvant maintenance therapy for patients with residual disease. This is the high-risk subgroup where the gold standard, maximum tolerated dose (MTD) chemotherapy, has clearly failed to eradicate the disease. The success of the CREATE-X trial in this specific, defined population—with its remarkable […]

Read More »

OncWonk – The AI Assisted Naturopathic Oncology Database

October 7, 2025
| No Comments
| Miscellaneous

Revolutionizing Naturopathic Oncology Research for Healthcare Professionals Contact Us for a complimentary 1 month trial. Introducing OncWonk, the groundbreaking AI-assisted Naturopathic Oncology Database meticulously curated to empower healthcare professionals with unparalleled access to cutting-edge research. This exclusive platform houses an expansive collection of nearly 120,000 articles from the medical literature dedicated to the exploration and […]

Read More »

OncWonk – Dr Bier's Oncology Research Reviews 2026 . Powered by WordPress